Genomics Medicine Ireland to create 600 jobs
11 December 2018
Irish life sciences firm Genomics Medicine Ireland, announces €350m investment programme aimed at making Ireland an important hub for genomics research and development of new disease treatments and cures
L-R: Robin Brainin, CEO, WuXi NextCODE; and Anne Jones, CEO GMI.
The Ireland Strategic Investment Fund (ISIF), an Irish sovereign development fund, WuXi NextCODE, the emerging global standard platform for genomics, and Irish life sciences company Genomics Medicine Ireland (GMI), has announced details of a $400 million (€350 million) investment programme aimed at making Ireland an important hub for genomics research and development of new disease treatments and cures.
Tech engine for leading population genomics efforts in Europe
Under the initiative, GMI will become a subsidiary of WuXi NextCODE, which serves as the technology engine for the leading population genomics efforts in Europe, the US and Asia. This will create up to 600 high-value jobs over five years and will position GMI as the cornerstone for a Silicon Docks-modelled International Centre for Advanced Life Sciences (ICALS).
Under the terms of the investment, $225 million (€197 million) will be committed to GMI in the near term increasing to $400 million in line with the achievement of milestones as GMI expands and an ICALS develops in the medium term.
Alongside ISIF, who are investing $70 million, major Silicon Valley and sovereign wealth funds and other global investors will also invest in the initiative through WuXi NextCODE and GMI. These include:
The launch investment will be focused on the expansion of GMI to undertake one of the world’s largest whole genome sequencing programmes. The programme will target participation from 400,000 volunteers, or one in every ten people in Ireland, including patients with a range of common and rare diseases.
Discovery of new precision medicines
This will help to deliver healthcare benefits to Irish patients and create a unique platform for research and discovery of new precision medicines for the treatment of life-limiting conditions which currently have no cure.
The initiative builds upon Ireland’s unique advantages for conducting population genomics research at scale:
1.) a relatively homogeneous population, which makes key genes easier to identify;
2.) a population large enough to have both common and rare diseases in significant numbers;
3.) high-quality healthcare and medical research facilities; and
4.) a demonstrable track record of high participation among the population in similar research programmes in the past.
To kick off the investment programme, the company proposes establishing a strategic advisory board comprised of experts and key stakeholders from academia, the health sector and industry to help foster the programme and maximise potential patient impact.
Provide core infrastructure of a global hub
GMI’s sizable population genomics programme as well as WuXi NextCODE’s genomics platform will be leveraged to provide core infrastructure of a global hub to attract Irish and international enterprises and organisations working in the life sciences industry including:
2.) Research and bioinformatics
3.) Precision medicine development
4.) Medical genetics services
5.) Digital health
6.) Cloud computing
7.) High performance computing and artificial intelligence
In addition to the investments, early-stage discussions to fund a genomics accelerator are already under way targeting further development of Ireland’s ecosystem in this field to support new start-ups and early-stage companies with similar specialist skills and research capabilities.
The potential for Ireland as an International Centre for Advanced Life Sciences can be seen from the experience of San Diego, California, which has a comparable population of about 3.3 million people.
San Diego has built an entire ecosystem around genomics and related life sciences sectors, yielding a $33.6 billion economic impact through more than 1,225 life sciences companies and 80 independent and university-affiliated research institutes together employing 37,790 people.
Taoiseach Leo Varadkar, TD, said:“GMI is a real Irish life sciences success story. In just three years since their founding they have proven their capacity to deliver and to grow and, in partnership with the state’s Strategic Investment Fund, are now poised for a further exciting period of expansion.
24 of world’s largest pharma and biotech companies located here
“GMI’s success is a reflection on the wider success of Ireland as a location for the life sciences industry for more than 50 years. Twenty-four of the world’s largest pharma and biotech companies are located here, creating valuable employment and contributing to our economic success.
“As a country, we have continuously worked to attract and retain investment from the life sciences sector and we are now positioning for the next wave of knowledge-driven innovation being led by the genomics industry and the economic benefits that will bring.
“With this partnership between GMI, ISIF and WuXi NextCODE we are creating an ecosystem of expertise in advanced life sciences right here in Ireland. That, in turn, will ultimately deliver better health and wellness management to people and patients in Ireland and turn the advances we make here into benefits for people around the world.”
Paul Saunders, Ireland strategic investment fund senior investment director, said: “This investment shows ISIF’s ability to act as a catalyst for major investment in high-value economic activity in Ireland by teaming up with top-tier co-investment partners from around the globe.
“Through ISIF’s investment in WuXi NextCODE, GMI should be well positioned to scale its activities significantly and quickly, generating new jobs in Ireland, and enhancing Ireland’s reputation as a centre for genomics research.
“This is an excellent example of ISIF’s ‘double bottom line’ mandate of supporting economic activity and employment in Ireland while seeking a commercial return.”
Anne Jones, CEO of Genomics Medicine Ireland, said: “WuXi NextCODE is a recognised global leader in the field and is helping to drive many national-scale precision medicine efforts.
Operational independence backed by global connections and funding
“This landmark investment in GMI will enable us to rapidly scale our study capacity to upwards of 60 disease areas in research sites across Ireland, giving us operational independence backed by global connections and funding.
“In doing so, Ireland – its people, hospitals, universities and enterprises – will benefit from a globally leading position in the most important new fields in life sciences.
“As a native of Tipperary who has spent the bulk of my career in major research institutions and healthcare companies in the US and UK, it is a thrilling opportunity to come back and be able to leverage WuXi NextCODE’s capabilities and global reach first for patients here, and in a way that will impact lives around the world.”
The announcement follows on from the recent announcement by WuXi NextCODE’s sister company, WuXi Biologics, supported by IDA Ireland, that it is establishing a biopharma facility in Dundalk that will create more than 400 jobs. WuXi NextCODE is also in discussions with IDA Ireland on this significant initiative.http://www.engineersjournal.ie/2018/12/11/genomics-medicine-ireland-to-create-600-jobs/http://www.engineersjournal.ie/wp-content/uploads/2018/11/genomics.pnghttp://www.engineersjournal.ie/wp-content/uploads/2018/11/genomics-300x300.pngNewscloud,jobs,life sciences